200 related articles for article (PubMed ID: 29453680)
1. Prognostic implications of
Toriihara A; Ohtake M; Tateishi K; Hino-Shishikura A; Yoneyama T; Kitazume Y; Inoue T; Kawahara N; Tateishi U
Ann Nucl Med; 2018 May; 32(4):264-271. PubMed ID: 29453680
[TBL] [Abstract][Full Text] [Related]
2. Redox reaction and clinical outcome of primary diffuse large B-cell lymphoma of the central nervous system: Prognostic role of metabolic and textural parameters of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET/computed tomography in a small patient cohort.
Tsuchiya J; Yoneyama T; Ohtake M; Tateishi K; Bae H; Kishino M; Tateishi U
Nucl Med Commun; 2020 Jun; 41(6):567-574. PubMed ID: 32371672
[TBL] [Abstract][Full Text] [Related]
3. Assessment of the Tumor Redox Status in Head and Neck Cancer by 62Cu-ATSM PET.
Tsujikawa T; Asahi S; Oh M; Sato Y; Narita N; Makino A; Mori T; Kiyono Y; Tsuchida T; Kimura H; Fujieda S; Okazawa H
PLoS One; 2016; 11(5):e0155635. PubMed ID: 27187778
[TBL] [Abstract][Full Text] [Related]
4. Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma.
Tateishi K; Tateishi U; Sato M; Yamanaka S; Kanno H; Murata H; Inoue T; Kawahara N
AJNR Am J Neuroradiol; 2013 Jan; 34(1):92-9. PubMed ID: 22700754
[TBL] [Abstract][Full Text] [Related]
5. Assessing tumor hypoxia in cervical cancer by positron emission tomography with 60Cu-ATSM: relationship to therapeutic response-a preliminary report.
Dehdashti F; Grigsby PW; Mintun MA; Lewis JS; Siegel BA; Welch MJ
Int J Radiat Oncol Biol Phys; 2003 Apr; 55(5):1233-8. PubMed ID: 12654432
[TBL] [Abstract][Full Text] [Related]
6. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).
Dehdashti F; Grigsby PW; Lewis JS; Laforest R; Siegel BA; Welch MJ
J Nucl Med; 2008 Feb; 49(2):201-5. PubMed ID: 18199612
[TBL] [Abstract][Full Text] [Related]
7. (62)Cu-diacetyl-bis (N(4)-methylthiosemicarbazone) PET in human gliomas: comparative study with [(18)F]fluorodeoxyglucose and L-methyl-[(11)C]methionine PET.
Tateishi K; Tateishi U; Nakanowatari S; Ohtake M; Minamimoto R; Suenaga J; Murata H; Kubota K; Inoue T; Kawahara N
AJNR Am J Neuroradiol; 2014 Feb; 35(2):278-84. PubMed ID: 23928140
[TBL] [Abstract][Full Text] [Related]
8. Tumor hypoxia detected by positron emission tomography with 60Cu-ATSM as a predictor of response and survival in patients undergoing Neoadjuvant chemoradiotherapy for rectal carcinoma: a pilot study.
Dietz DW; Dehdashti F; Grigsby PW; Malyapa RS; Myerson RJ; Picus J; Ritter J; Lewis JS; Welch MJ; Siegel BA
Dis Colon Rectum; 2008 Nov; 51(11):1641-8. PubMed ID: 18682881
[TBL] [Abstract][Full Text] [Related]
9. Assessment of tumor hypoxia by 62Cu-ATSM PET/CT as a predictor of response in head and neck cancer: a pilot study.
Minagawa Y; Shizukuishi K; Koike I; Horiuchi C; Watanuki K; Hata M; Omura M; Odagiri K; Tohnai I; Inoue T; Tateishi U
Ann Nucl Med; 2011 Jun; 25(5):339-45. PubMed ID: 21327756
[TBL] [Abstract][Full Text] [Related]
10. Pathophysiologic correlation between 62Cu-ATSM and 18F-FDG in lung cancer.
Lohith TG; Kudo T; Demura Y; Umeda Y; Kiyono Y; Fujibayashi Y; Okazawa H
J Nucl Med; 2009 Dec; 50(12):1948-53. PubMed ID: 19910425
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
Kinoshita T; Fujii H; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H
Lung Cancer; 2016 Jan; 91():56-66. PubMed ID: 26711935
[TBL] [Abstract][Full Text] [Related]
12. Multimodality functional imaging of spontaneous canine tumors using 64Cu-ATSM and 18FDG PET/CT and dynamic contrast enhanced perfusion CT.
Hansen AE; Kristensen AT; Law I; McEvoy FJ; Kjær A; Engelholm SA
Radiother Oncol; 2012 Mar; 102(3):424-8. PubMed ID: 22119225
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
[TBL] [Abstract][Full Text] [Related]
14. Usefulness of 64Cu-ATSM in head and neck cancer: a preliminary prospective study.
Grassi I; Nanni C; Cicoria G; Blasi C; Bunkheila F; Lopci E; Colletti PM; Rubello D; Fanti S
Clin Nucl Med; 2014 Jan; 39(1):e59-63. PubMed ID: 24097008
[TBL] [Abstract][Full Text] [Related]
15. Assessing tumor hypoxia in head and neck cancer by PET with ⁶²Cu-diacetyl-bis(N⁴-methylthiosemicarbazone).
Sato Y; Tsujikawa T; Oh M; Mori T; Kiyono Y; Fujieda S; Kimura H; Okazawa H
Clin Nucl Med; 2014 Dec; 39(12):1027-32. PubMed ID: 25140555
[TBL] [Abstract][Full Text] [Related]
16. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
Dence CS; Ponde DE; Welch MJ; Lewis JS
Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
[TBL] [Abstract][Full Text] [Related]
17. In vivo assessment of tumor hypoxia in lung cancer with 60Cu-ATSM.
Dehdashti F; Mintun MA; Lewis JS; Bradley J; Govindan R; Laforest R; Welch MJ; Siegel BA
Eur J Nucl Med Mol Imaging; 2003 Jun; 30(6):844-50. PubMed ID: 12692685
[TBL] [Abstract][Full Text] [Related]
18. Heterogeneity in intratumor correlations of 18F-FDG, 18F-FLT, and 61Cu-ATSM PET in canine sinonasal tumors.
Bradshaw TJ; Bowen SR; Jallow N; Forrest LJ; Jeraj R
J Nucl Med; 2013 Nov; 54(11):1931-7. PubMed ID: 24042031
[TBL] [Abstract][Full Text] [Related]
19. Tumor hypoxia and microscopic diffusion capacity in brain tumors: a comparison of (62)Cu-Diacetyl-Bis (N4-Methylthiosemicarbazone) PET/CT and diffusion-weighted MR imaging.
Hino-Shishikura A; Tateishi U; Shibata H; Yoneyama T; Nishii T; Torii I; Tateishi K; Ohtake M; Kawahara N; Inoue T
Eur J Nucl Med Mol Imaging; 2014 Jul; 41(7):1419-27. PubMed ID: 24719157
[TBL] [Abstract][Full Text] [Related]
20. A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].
Furukawa T; Yuan Q; Jin ZH; Aung W; Yoshii Y; Hasegawa S; Endo H; Inoue M; Zhang MR; Fujibayashi Y; Saga T
Oncol Rep; 2015 Sep; 34(3):1379-87. PubMed ID: 26134305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
